Table 2.
Summary of univariate analyses for overall survival, freedom from distant metastasis, and freedom from locoregional recurrence (n = 79)
| Variable | OS |
FFDM |
FFLR |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Reirradiation (yes vs no) | 1.3 (0.5-3.5) | .62 | 0.7 (0.2-2.3) | .53 | 0.27 (0.03-2.1) | .21 |
| Concurrent Chemotherapy (yes vs no) | 0.9 (0.4-2.1) | .78 | 2.3 (0.8-6.7) | .11 | 1.8 (0.6-5.7) | .33 |
| ECOG (2 or 3 vs 0 or 1) | 2.9 (1.2-7.1) | .02 | 2.0 (0.6-6.2) | .24 | 0.4 (0.04-2.7) | .31 |
| Sex (female vs male) | 0.6 (0.2-1.5) | .26 | 0.7 (0.3-1.6) | .36 | 0.3 (0.1-1.0) | .06 |
| Age (per y) | 1.0 (1.0-1.1) | .08 | 0.95 (0.9-1.0) | .03 | 1.0 (0.9-1.0) | .11 |
| Received RT dose (per Gy) | 0.9 (0.8-1.0) | .06 | 1.0 (0.9-1.1) | 1.00 | 1.2 (1.0-1.3) | .01 |
| Smoking (Smoked vs never) | 0.89 (0.3-2.6) | .83 | 0.7 (0.2-2.2) | .56 | 0.4 (0.1-1.1) | .07 |
| Modality (IMPT vs IMRT) | 1.1 (0.4-2.6) | .87 | 0.7 (0.3-2.1) | .58 | 0.3 (0.1-1.4) | .13 |
| Kidney disease | 1.7 (0.5-5.7) | .41 | 1.6 (0.5-5.7) | .45 | 0.6 (0.1-4.9) | .66 |
| (yes vs no) | 1.4 (0.6-3.4) | .42 | 0.7 (0.3-1.9) | .50 | 0.3 (0.1-1.1) | .08 |
| Hypertension | ||||||
| (yes vs no) | 2.6 (0.9-7.1) | .07 | 2.2 (0.62-7.5) | .23 | 1.5 (0.3-6.7) | .60 |
| Diabetes | ||||||
| (yes vs no) | 1.8 (0.7-5.0) | .25 | 0.3 (0.04-2.6) | .29 | 0.4 (0.1-3.3) | .42 |
| CAD (yes vs no) | ||||||
Abbreviations: CAD = coronary artery disease; CI = confidence interval; FFDM = freedom from distant metastasis; FFLR = freedom from locoregional recurrence; HR = hazard ratio; IMPT = intensity-modulated proton therapy; IMRT = intensity-modulated radiation therapy; OS = overall survival; RT = radiation therapy.